RGC
Roberts, Glore & Co Portfolio holdings
AUM
$342M
1-Year Est. Return
15.34%
1 Year Est. Return
+15.34%
AUM
$328M
AUM Growth
-$9.02M
(-2.7%)
Holding
213
Top Buys
| 1 | +$981K | |
| 2 | +$710K | |
| 3 | +$552K | |
| 4 |
ASML
ASML
|
+$492K |
| 5 |
Adams Diversified Equity Fund
ADX
|
+$364K |
Top Sells
| 1 | +$1.71M | |
| 2 | +$1.18M | |
| 3 | +$964K | |
| 4 |
Apple
AAPL
|
+$911K |
| 5 |
CVS Health
CVS
|
+$647K |
Sector Composition
| 1 | Technology | 16.85% |
| 2 | Healthcare | 16.12% |
| 3 | Financials | 14.31% |
| 4 | Industrials | 8.77% |
| 5 | Communication Services | 6.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Ambev
ABEV
$35.1B
| $80.3K | 0.02% |
34,480
|
|
||
202
Albemarle
ALB
$10.9B
| – | – |
-2,883
|
|
||
203
Charles River Laboratories
CRL
$8.79B
| – | – |
-5,223
|
|
||
|
204
CVS Health
CVS
$105B
| – | – |
-14,407
|
|
||
205
Dell
DELL
$100B
| – | – |
-1,877
|
|
||
206
First Solar
FSLR
$24.9B
| – | – |
-1,158
|
|
||
207
Illumina
ILMN
$14.7B
| – | – |
-2,670
|
|
||
208
Morningstar
MORN
$9.05B
| – | – |
-610
|
|
||
209
Neurocrine Biosciences
NBIX
$13.9B
| – | – |
-1,492
|
|
||
210
Organon & Co
OGN
$2.41B
| – | – |
-13,826
|
|
||
211
T. Rowe Price
TROW
$22.8B
| – | – |
-1,875
|
|
||
212
UFP Industries
UFPI
$5.31B
| – | – |
-1,788
|
|
||
213
United States Lime & Minerals
USLM
$3.8B
| – | – |
-2,300
|
|